Laropiprant
CAS : 571170-77-9
Ref. 3D-FC75279
10mg | 222,00 € | ||
25mg | 411,00 € | ||
50mg | 548,00 € | ||
100mg | 867,00 € | ||
250mg | 1.625,00 € |
Informations sur le produit
- (-)-[(3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
- (3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)cyclopent[b]indole-3-acetic acid
- (R)-2-(4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
- 2-[(3R)-4-[(4-Chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid
- Cardaptive
- Cyclopent[b]indole-3-acetic acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3R)-
- Mk-0524
- [(3R)-4-(4-Chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
Laropiprant is a drug that is designed to lower the levels of LDL cholesterol in the blood. It has been shown to be effective for long-term use and has metabolic effects with limited side effects. Laropiprant lowers LDL cholesterol by decreasing the production of prostaglandin J2 and increasing the excretion of bile acids, which are produced as a result of increased camp levels. The enzyme responsible for hepatic glucuronidation is inhibited by laropiprant, which leads to increased levels of its active form. Laropiprant also inhibits atherosclerosis through an in vitro method that involves human macrophages.
Propriétés chimiques
Question d’ordre technique sur : 3D-FC75279 Laropiprant
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages